Chief Medical Officer, Veracyte Inc ; CEO, Genomics Institute Inc.
Oncology
Dr. Neil M. Barth, MD
|
|
Give Review
Neil Barth practices Oncology. He researched medicine at University of Toledo College of Medicine. He received 4 awards: "CMS Meaningful Use Stage 1 Certification", "Super Doctor", "Most Compassionate Doctor" and "Top MD". Neil Barth is a published doctor and has 32 publications published. The lastest was: 'Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid...'
Publications
- Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic Melanoma?
- Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?
- Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with...
- Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastat...
- High-dose chemotherapy and autologous stem cell rescue for metastatic breast Cancer: superior survival for tandem compared with single transplants.
- Does continuous-infusion interleukin-2 increase survival in metastatic Melanoma?
- Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic Cancer: induction of delayed-type hypersensitivit...
- Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell Carcinoma.
- Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas.
- Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic Melanoma.
- Long-term survival after continuous infusion interleukin-2.
- Treatment of kidney Cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
- Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and coloRectal cancer.
- Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim Analysis.
- High-dose chemotherapy with autologous stem cell rescue in breast Cancer.
- The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community Cancer cen...
- Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced Melanoma. A national biotherapy study group trial.
- Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in Melanoma: a National Biotherapy Study Group trial.
- Continuous interleukin-2 and lymphokine-activated killer cells for advanced Cancer: a National Biotherapy Study Group trial.
- Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic Cancer.
- Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic Melanoma.
- Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma.
- Intensive chemotherapy with autologous peripheral-blood stem-cell rescue in metastatic breast Cancer.
- Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid...
- Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid Tumors: a National Biotherapy Study Group Trial.
- Malignant melanoma and pregnancy ten questions.
- A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced ...
- Continuous infusion of interleukin-2 and cyclophosphamide as treatment of advanced Cancers: a National Biotherapy Study Group Trial.
- Gly15Gly polymorphism within the human adipocyte-specific apM-1gene but not Tyr111His polymorphism is associated with higher levels of cholesterol and LDL-cholesterol ...
- Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol i...
- Partial resolution of Acute ascending motor polyneuropathy after enucleation of an eye with metastatic melanoma.
Schools
Medical College Of Ohio
Harbor UCLA Med Center
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
- Most Compassionate Doctor
- Top MD
Education
-
Harbor - UCLA Medical Center -
University of Toledo College of Medicine
Hospital
-
Hoag Memorial Hospital Presbyterian
Helpful Reviews
Similar Doctors
|
Dr. Anthony Ciarolla, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Schlutz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Greg R. Angstreich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Warren H. Fong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andreea Nanci, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Khosrow Mahdavi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John S. Cupp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert O. Dillman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Monica P. Mosquera Caro, MD
This Doctor is OpenDoctor Recommended.
|